Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (AlloPBHCT) with TBI-Based Conditioning Regimens

✍ Scribed by Burns, Michael; Singh, Anurag; Zhang, Yali; Chen, George L.; Liu, Hong; Ross, Maureen; McCarthy, Philip L.; Hahn, Theresa

• Book ID: 122240156
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 218 KB
• Volume: 20
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2013.12.016